International Stem Cell Corp - Understand $isco stock

$ISCO Market Cap: $560.3 Thousand

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$8.528M

TTM

Gross Margin

57.2%

TTM

Net Earnings

-$523.0K

TTM

Current Assets

$3.490M

Q3 2024

Current Liabilities

$4.718M

Q3 2024

Current Ratio

73.97%

Q3 2024

Total Assets

$5.180M

Q3 2024

Total Liabilities

$4.921M

Q3 2024

Book Value

$259.0K

Q3 2024

Cash

$1.307M

Q3 2024

P/E

-1.071

Nov 29, 2024 EST

Free Cash Flow

$81.00K

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	$7.789M	$8.180M	$7.176M	$7.128M	$9.472M	$11.09M	$7.456M	$7.165M	$7.551M	$7.017M	$6.147M	$4.567M	$4.530M	$1.570M	$1.120M	$500.0K	$40.00K	$0.00
YoY Change	-4.78%	13.99%	0.67%	-24.75%	-14.58%	48.73%	4.06%	-5.11%	7.61%	14.15%	34.6%	0.82%	188.54%	40.18%	124.0%	1150.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	$7.789M	$8.180M	$7.176M	$7.128M	$9.472M	$11.09M	$7.456M	$7.165M	$7.551M	$7.017M	$6.147M	$4.567M	$4.530M	$1.570M	$1.120M	$500.0K	$40.00K	$0.00
Cost Of Revenue	$3.181M	$3.269M	$2.935M	$2.781M	$3.933M	$4.069M	$2.122M	$1.944M	$2.056M	$1.921M	$1.643M	$1.272M	$1.620M	$720.0K	$790.0K	$130.0K	$40.00K	$30.00K
Gross Profit	$4.608M	$4.911M	$4.241M	$4.347M	$5.539M	$7.020M	$5.334M	$5.221M	$5.495M	$5.096M	$4.504M	$3.295M	$2.910M	$840.0K	$330.0K	$370.0K	$0.00	-$30.00K
Gross Profit Margin	59.16%	60.04%	59.1%	60.98%	58.48%	63.31%	71.54%	72.87%	72.77%	72.62%	73.27%	72.15%	64.24%	53.5%	29.46%	74.0%	0.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Selling, General & Admin	$4.760M	$4.602M	$5.467M	$6.177M	$8.341M	$8.098M	$7.618M	$7.216M	$7.352M	$8.390M	$8.490M	$9.511M	$9.840M	$7.930M	$5.370M	$3.960M	$3.580M	$3.830M
YoY Change	3.43%	-15.82%	-11.49%	-25.94%	3.0%	6.3%	5.57%	-1.85%	-12.37%	-1.18%	-10.73%	-3.34%	24.09%	47.67%	35.61%	10.61%	-6.53%
% of Gross Profit	103.3%	93.71%	128.91%	142.1%	150.59%	115.36%	142.82%	138.21%	133.79%	164.64%	188.5%	288.65%	338.14%	944.05%	1627.27%	1070.27%
Research & Development	$511.0K	$492.0K	$695.0K	$988.0K	$1.386M	$2.279M	$2.519M	$2.734M	$2.608M	$5.386M	$3.560M	$3.599M	$4.430M	$3.370M	$2.160M	$1.950M	$2.490M	$1.860M
YoY Change	3.86%	-29.21%	-29.66%	-28.72%	-39.18%	-9.53%	-7.86%	4.83%	-51.58%	51.29%	-1.08%	-18.76%	31.45%	56.02%	10.77%	-21.69%	33.87%
% of Gross Profit	11.09%	10.02%	16.39%	22.73%	25.02%	32.46%	47.23%	52.37%	47.46%	105.69%	79.04%	109.23%	152.23%	401.19%	654.55%	527.03%
Depreciation & Amortization	$194.0K	$218.0K	$262.0K	$253.0K	$285.0K	$308.0K	$326.0K	$331.0K	$472.0K	$458.0K	$464.0K	$474.0K	$490.0K	$290.0K	$210.0K	$160.0K	$140.0K	$80.00K
YoY Change	-11.01%	-16.79%	3.56%	-11.23%	-7.47%	-5.52%	-1.51%	-29.87%	3.06%	-1.29%	-2.11%	-3.27%	68.97%	38.1%	31.25%	14.29%	75.0%
% of Gross Profit	4.21%	4.44%	6.18%	5.82%	5.15%	4.39%	6.11%	6.34%	8.59%	8.99%	10.3%	14.39%	16.84%	34.52%	63.64%	43.24%
Operating Expenses	$5.271M	$5.094M	$6.162M	$7.165M	$9.727M	$10.49M	$7.618M	$10.07M	$10.06M	$13.78M	$12.05M	$13.11M	$14.27M	$11.31M	$7.530M	$5.910M	$6.070M	$5.690M
YoY Change	3.47%	-17.33%	-14.0%	-26.34%	-7.31%	37.75%	-24.36%	0.13%	-26.98%	14.32%	-8.09%	-8.13%	26.17%	50.2%	27.41%	-2.64%	6.68%
Operating Profit	-$663.0K	-$183.0K	-$1.921M	-$2.818M	-$5.728M	-$3.474M	-$4.942M	-$4.851M	-$4.564M	-$8.680M	-$7.546M	-$9.815M	-$11.36M	-$10.47M	-$7.200M	-$5.540M	-$6.070M	-$5.720M
YoY Change	262.3%	-90.47%	-31.83%	-50.8%	64.88%	-29.7%	1.88%	6.29%	-47.42%	15.03%	-23.12%	-13.6%	8.5%	45.42%	29.96%	-8.73%	6.12%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Interest Expense	$139.0K	$135.0K	$128.0K	$113.0K	$77.00K	$48.00K	$59.00K	$6.000K	$11.00K	-$1.042M	$3.000K	$2.000K	$2.340M	-$2.490M	-$580.0K	-$1.050M	-$10.00K	-$780.0K
YoY Change	2.96%	5.47%	13.27%	46.75%	60.42%	-18.64%	883.33%	-45.45%	-101.06%	-34833.33%	50.0%	-99.91%	-193.98%	329.31%	-44.76%	10400.0%	-98.72%
% of Operating Profit
Other Income/Expense, Net	$532.0K	-$148.0K	$1.022M	$94.00K	$1.463M	$1.343M	-$1.127M	$3.772M	$1.929M	-$3.798M	-$2.933M	-$18.00K	-$150.0K	$230.0K	$10.00K	$10.00K	$10.00K	$10.00K
YoY Change	-459.46%	-114.48%	987.23%	-93.57%	8.94%	-219.17%	-129.88%	95.54%	-150.79%	29.49%	16194.44%	-88.0%	-165.22%	2200.0%	0.0%	0.0%	0.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Pretax Income	-$131.0K	-$331.0K	-$899.0K	-$2.724M	-$4.265M	-$2.131M	-$6.069M	-$1.079M	-$2.635M	-$12.48M	-$10.48M	-$9.833M	-$9.170M	-$12.72M	-$7.770M	-$6.570M	-$6.070M	-$6.580M
YoY Change	-60.42%	-63.18%	-67.0%	-36.13%	100.14%	-64.89%	462.47%	-59.05%	-78.88%	19.08%	6.57%	7.23%	-27.91%	63.71%	18.26%	8.24%	-7.75%
Income Tax						$0.00	$0.00	$0.00	$0.00	$0.00	$0.00		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$131.0K	-$331.0K	-$899.0K	-$2.724M	-$4.265M	-$2.131M	-$6.069M	-$1.079M	-$2.635M	-$12.48M	-$10.48M	-$9.833M	-$9.171M	-$12.72M	-$8.513M	-$6.571M	-$6.072M	-$6.584M
YoY Change	-60.42%	-63.18%	-67.0%	-36.13%	100.14%	-64.89%	462.47%	-59.05%	-78.88%	19.08%	6.57%	7.22%	-27.92%	49.45%	29.55%	8.22%	-7.78%
Net Earnings / Revenue	-1.68%	-4.05%	-12.53%	-38.22%	-45.03%	-19.22%	-81.4%	-15.06%	-34.9%	-177.83%	-170.47%	-215.31%	-202.45%	-810.38%	-760.09%	-1314.2%	-15180.0%
Basic Earnings Per Share	-$0.02	-$0.04	-$0.11			-$0.33	-$1.46	-$0.34	-$1.33	-$9.71
Diluted Earnings Per Share	-$0.02	-$0.04	-$114.8K	-$361.3K	-$567.7K	-$0.33	-$1.46	-$0.34	-$1.328M	-$9.708M	-$12.78M	-$17.25M	-$17.98M	-$27.65M	-$25.06M	-$27.38M	-$25.29M	-$43.87M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Cash & Short-Term Investments	$1.588M	$742.0K	$171.0K	$689.0K	$484.0K	$1.075M	$304.0K	$110.0K	$532.0K	$1.111M	$2.240M	$650.0K	$1.340M	$5.780M	$730.0K	$380.0K	$170.0K	$4.700M
YoY Change	114.02%	333.92%	-75.18%	42.36%	-54.98%	253.62%	176.36%	-79.32%	-52.12%	-50.4%	244.62%	-51.49%	-76.82%	691.78%	92.11%	123.53%	-96.38%
Cash & Equivalents						$1.075M	$304.0K	$110.0K	$532.0K	$1.111M	$2.240M	$650.0K	$1.340M	$5.780M	$730.0K	$380.0K	$170.0K	$4.700M
Short-Term Investments
Other Short-Term Assets	$96.00K	$90.00K	$135.0K	$174.0K	$207.0K	$543.0K	$779.0K	$418.0K	$572.0K	$485.0K	$710.0K	$460.0K	$270.0K	$230.0K	$250.0K	$80.00K	$120.0K	$0.00
YoY Change	6.67%	-33.33%	-22.41%	-15.94%	-61.88%	-30.3%	86.36%	-26.92%	17.94%	-31.69%	54.35%	70.37%	17.39%	-8.0%	212.5%	-33.33%
Inventory	$1.263M	$1.384M	$1.184M	$917.0K	$1.246M	$1.501M	$1.307M	$1.390M	$1.348M	$1.517M	$1.370M	$1.200M	$1.270M	$860.0K	$630.0K	$420.0K	$180.0K	$20.00K
Prepaid Expenses
Receivables	$574.0K	$747.0K	$844.0K	$403.0K	$1.515M	$651.0K	$465.0K	$574.0K	$539.0K	$453.0K	$310.0K	$270.0K	$140.0K	$740.0K	$130.0K	$80.00K	$10.00K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.521M	$2.963M	$2.334M	$2.183M	$3.452M	$3.770M	$2.855M	$2.492M	$2.991M	$3.616M	$4.630M	$2.580M	$3.020M	$7.600M	$1.740M	$960.0K	$470.0K	$4.720M
YoY Change	18.83%	26.95%	6.92%	-36.76%	-8.44%	32.05%	14.57%	-16.68%	-17.28%	-21.9%	79.46%	-14.57%	-60.26%	336.78%	81.25%	104.26%	-90.04%
Property, Plant & Equipment	$772.0K	$975.0K	$1.252M	$1.408M	$1.385M	$469.0K	$321.0K	$396.0K	$375.0K	$714.0K	$830.0K	$1.130M	$1.420M	$1.300M	$1.210M	$630.0K	$480.0K	$140.0K
YoY Change	-20.82%	-22.12%	-11.08%	1.66%	195.31%	46.11%	-18.94%	5.6%	-47.48%	-13.98%	-26.55%	-20.42%	9.23%	7.44%	92.06%	31.25%	242.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$297.0K	$319.0K	$411.0K	$434.0K	$448.0K	$883.0K	$766.0K	$673.0K	$549.0K	$54.00K	$30.00K	$20.00K	$20.00K	$40.00K	$20.00K	$20.00K	$20.00K	$20.00K
YoY Change	-6.9%	-22.38%	-5.3%	-3.13%	-49.26%	15.27%	13.82%	22.59%	916.67%	80.0%	50.0%	0.0%	-50.0%	100.0%	0.0%	0.0%	0.0%
Total Long-Term Assets	$1.869M	$2.172M	$2.612M	$3.104M	$3.168M	$4.026M	$4.009M	$4.553M	$4.147M	$3.563M	$3.110M	$2.790M	$2.720M	$2.330M	$1.960M	$1.280M	$1.130M	$830.0K
YoY Change	-13.95%	-16.85%	-15.85%	-2.02%	-21.31%	0.42%	-11.95%	9.79%	16.39%	14.57%	11.47%	2.57%	16.74%	18.88%	53.13%	13.27%	36.14%
Total Assets	$5.390M	$5.135M	$4.946M	$5.287M	$6.620M	$7.796M	$6.864M	$7.045M	$7.138M	$7.179M	$7.740M	$5.370M	$5.740M	$9.930M	$3.700M	$2.240M	$1.600M	$5.550M
YoY Change
Accounts Payable	$364.0K	$322.0K	$508.0K	$360.0K	$654.0K	$458.0K	$830.0K	$841.0K	$1.092M	$670.0K	$530.0K	$970.0K	$890.0K	$580.0K	$370.0K	$470.0K	$490.0K	$320.0K
YoY Change	13.04%	-36.61%	41.11%	-44.95%	42.79%	-44.82%	-1.31%	-22.99%	62.99%	26.42%	-45.36%	8.99%	53.45%	56.76%	-21.28%	-4.08%	53.13%
Accrued Expenses	$761.0K	$738.0K	$583.0K	$732.0K	$1.009M	$579.0K	$607.0K	$465.0K	$834.0K	$1.711M	$1.290M	$730.0K	$750.0K	$550.0K	$630.0K	$230.0K	$140.0K	$20.00K
YoY Change	3.12%	26.59%	-20.36%	-27.45%	74.27%	-4.61%	30.54%	-44.24%	-51.26%	32.64%	76.71%	-2.67%	36.36%	-12.7%	173.91%	64.29%	600.0%
Deferred Revenue
YoY Change
Short-Term Debt	$3.457M	$3.325M	$2.943M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	3.97%	12.98%
Long-Term Debt Due			$0.00	$141.0K
YoY Change			-100.0%
Total Short-Term Liabilities	$4.832M	$4.635M	$4.284M	$1.483M	$1.913M	$5.077M	$4.800M	$3.601M	$5.544M	$6.858M	$7.020M	$2.190M	$2.110M	$4.540M	$2.820M	$1.810M	$1.390M	$850.0K
YoY Change	4.25%	8.19%	188.87%	-22.48%	-62.32%	5.77%	33.3%	-35.05%	-19.16%	-2.31%	220.55%	3.79%	-53.52%	60.99%	55.8%	30.22%	63.53%
Long-Term Debt	$0.00	$0.00	$0.00	$2.992M	$2.370M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change			-100.0%	26.24%
Other Long-Term Liabilities	$445.0K	$720.0K	$950.0K	$845.0K	$925.0K	$182.0K			$0.00	$0.00				$0.00	$2.030M	$0.00
YoY Change	-38.19%	-24.21%	12.43%	-8.65%	408.24%									-100.0%
Total Long-Term Liabilities	$445.0K	$720.0K	$950.0K	$3.837M	$3.295M	$182.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$2.030M	$0.00	$0.00	$0.00
YoY Change	-38.19%	-24.21%	-75.24%	16.45%	1710.44%									-100.0%
Total Liabilities	$5.277M	$5.355M	$5.234M	$5.320M	$5.208M	$5.259M	$4.800M	$3.601M	$5.544M	$6.858M	$7.020M	$2.190M	$2.110M	$4.540M	$4.860M	$1.810M	$1.390M	$850.0K
YoY Change	-1.46%	2.31%	-1.62%	2.15%	-0.97%	9.56%	33.3%	-35.05%	-19.16%	-2.31%	220.55%	3.79%	-53.52%	-6.58%	168.51%	30.22%	63.53%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2018	2017	2016	2015	2014
Basic Shares Outstanding	8.004M	8.004M	7.833M	6.388M	4.158M	3.190M	1.984M	1.285M
Diluted Shares Outstanding	8.004M	8.004M	7.833M	6.388M	4.158M	3.190M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $560.31 Thousand

About International Stem Cell CORP

International Stem Cell Corp. operates as a research and development company for the therapeutic market. The company is headquartered in San Diego, California and currently employs 29 full-time employees. The company went IPO on 2006-09-25. The firm is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The firm's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The firm's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.

Industry: Pharmaceutical Preparations Peers: ACTAVIA LIFE SCIENCES, INC. Allena Pharmaceuticals, Inc. GlobeStar Therapeutics Corp Qrons Inc. Histogen Inc. NovAccess Global Inc.